Prolonged effects of short‐term anti‐CD20 B cell depletion therapy in murine systemic lupus erythematosus
Open Access
- 3 August 2010
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 62 (8), 2443-2457
- https://doi.org/10.1002/art.27515
Abstract
Objective Although B cells are implicated in the pathogenesis of systemic lupus erythematosus, the role of B cell depletion (BCD) as a treatment is controversial, given the variable benefit in human disease. This study was undertaken to test the effects of BCD therapy in a murine lupus model to better understand the mechanisms, heterogeneity, and effects on disease outcomes. Methods (NZB × NZW)F1 female mice with varying degrees of disease severity were treated with an anti‐mouse CD20 (anti‐mCD20) antibody (IgG2a), BR3‐Fc fusion protein (for BAFF blockade), or control anti‐human CD20 monoclonal antibody (∼10 mg/kg each). Tissue samples were harvested and analyzed by flow cytometry. The development and extent of nephritis were assessed by monitoring proteinuria (using a urine dipstick) and by immunohistochemical analysis of the kidneys. Serum immunoglobulin levels were measured by enzyme‐linked immunosorbent assay. Results After a single injection of anti‐mCD20, BCD was more efficient in the peripheral blood, lymph nodes, and spleen compared with the bone marrow and peritoneum of normal mice as well as younger mice with lupus. Since depletion of the marginal zone and peritoneal B cells was incomplete and variable, particularly in older mice with established nephritis, a strategy of sequential weekly dosing was subsequently used, which improved the extent of depletion. BAFF blockade further enhanced depletion in the spleen and lymph nodes. Early BCD therapy delayed disease onset, whereas BCD therapy in mice with advanced disease reduced the progression of nephritis. These effects were long‐lasting, even after B cell reconstitution occurred, and were associated with a reduction in T cell activation but no significant change in autoantibody production. Conclusion The lasting benefit of a short course of BCD therapy in lupus‐prone mice with an intact immune system and established disease highlights the validity of this treatment approach.Keywords
This publication has 51 references indexed in Scilit:
- Insights into the heterogeneity of human B cells: diverse functions, roles in autoimmunity, and use as therapeutic targetsImmunologic Research, 2009
- Regulatory B cells inhibit EAE initiation in mice while other B cells promote disease progressionJCI Insight, 2008
- Cytokine-producing B lymphocytes—key regulators of immunityCurrent Opinion in Immunology, 2008
- A Regulatory B Cell Subset with a Unique CD1dhiCD5+ Phenotype Controls T Cell-Dependent Inflammatory ResponsesImmunity, 2008
- Maintenance of the plasma cell pool is independent of memory B cellsProceedings of the National Academy of Sciences of the United States of America, 2008
- Therapeutic B cell depletion impairs adaptive and autoreactive CD4+T cell activation in miceProceedings of the National Academy of Sciences of the United States of America, 2007
- Treatment with CD20-specific antibody prevents and reverses autoimmune diabetes in miceJCI Insight, 2007
- B‐lymphocyte depletion ameliorates Sjögren's syndrome in Id3 knockout miceImmunology, 2007
- B cell depletion therapy in systemic lupus erythematosus: long-term follow-up and predictors of responseAnnals Of The Rheumatic Diseases, 2007
- B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose‐escalation trial of rituximabArthritis & Rheumatism, 2004